Compare Stocks → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALRNNASDAQ:APRENASDAQ:LMNLNASDAQ:MBRXNASDAQ:RZLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$4.75$5.40$1.01▼$7.42$80.61M2.2264,087 shs67,714 shsAPREAprea Therapeutics$5.37+4.9%$6.43$2.78▼$8.85$29.16M1.0329,875 shs2,607 shsLMNLLiminal BioSciences$8.50+0.1%$8.47$3.10▼$8.50$26.35M1.0363,470 shs5,000 shsMBRXMoleculin Biotech$4.60+7.0%$6.87$4.28▼$15.75$10.26M1.9630,096 shs7,427 shsRZLTRezolute$2.86-19.2%$2.13$0.72▼$3.69$114.77M1.29312,043 shs939,517 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics0.00%-11.21%-23.39%+3.04%+227.63%APREAprea Therapeutics+4.07%-5.79%-12.25%-4.62%+37.40%LMNLLiminal BioSciences0.00%0.00%0.00%0.00%+27.82%MBRXMoleculin Biotech+6.98%+6.24%-19.36%-39.54%-59.11%RZLTRezolute-19.21%-15.88%+43.00%+163.59%+34.91%The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron Therapeutics2.0721 of 5 stars3.53.00.00.02.91.70.0APREAprea Therapeutics3.3885 of 5 stars3.55.00.00.02.23.30.6LMNLLiminal BioSciencesN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech2.1795 of 5 stars3.53.00.00.02.40.01.3RZLTRezolute3.3115 of 5 stars3.53.00.00.03.14.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics3.00Buy$19.00300.00% UpsideAPREAprea Therapeutics3.00Buy$15.50188.64% UpsideLMNLLiminal BioSciencesN/AN/AN/AN/AMBRXMoleculin Biotech3.00Buy$35.00660.87% UpsideRZLTRezolute3.00Buy$8.80207.69% UpsideCurrent Analyst RatingsLatest APRE, ALRN, MBRX, LMNL, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.004/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/12/2024MBRXMoleculin BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/27/2024APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$9.00 ➝ $11.003/26/2024APREAprea TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.003/7/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/14/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AAPREAprea Therapeutics$580K50.27N/AN/A$4.54 per share1.18LMNLLiminal BioSciences$310K85.00N/AN/A$8.97 per share0.95MBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/ARZLTRezoluteN/AN/AN/AN/A$3.15 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)APREAprea Therapeutics-$14.29M-$3.99N/AN/AN/AN/A-65.58%-52.37%5/20/2024 (Estimated)LMNLLiminal BioSciences$380K$0.2929.31∞N/A248.35%-88.44%-64.15%N/AMBRXMoleculin Biotech-$29.77M-$13.64N/AN/AN/AN/A-80.91%-67.69%5/9/2024 (Estimated)RZLTRezolute-$51.79M-$1.10N/AN/AN/AN/A-51.81%-48.05%5/9/2024 (Estimated)Latest APRE, ALRN, MBRX, LMNL, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023APREAprea Therapeutics-$0.56-$0.92-$0.36-$0.92$0.33 million$0.01 million2/13/2024Q2 2024RZLTRezolute-$0.27-$0.27N/A-$0.27N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/AAPREAprea TherapeuticsN/AN/AN/AN/AN/ALMNLLiminal BioSciencesN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A4.174.17APREAprea TherapeuticsN/A5.135.13LMNLLiminal BioSciences0.022.782.78MBRXMoleculin BiotechN/A3.863.86RZLTRezoluteN/A12.0012.00OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%APREAprea Therapeutics34.19%LMNLLiminal BioSciences0.66%MBRXMoleculin Biotech15.52%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.57%APREAprea Therapeutics20.90%LMNLLiminal BioSciences2.20%MBRXMoleculin Biotech6.70%RZLTRezolute18.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableAPREAprea Therapeutics75.43 million4.30 millionNo DataLMNLLiminal BioSciences2513.10 million3.04 millionNot OptionableMBRXMoleculin Biotech182.23 million2.08 millionNot OptionableRZLTRezolute5740.13 million32.83 millionNot OptionableAPRE, ALRN, MBRX, LMNL, and RZLT HeadlinesSourceHeadlinePhase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meetingglobenewswire.com - April 23 at 8:00 AMRezolute (NASDAQ:RZLT) Now Covered by Jonestradingamericanbankingnews.com - April 20 at 4:42 AMRezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by JMP Securitiesamericanbankingnews.com - April 20 at 1:54 AMJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy Recommendationmsn.com - April 19 at 8:15 AMRezolute (NASDAQ:RZLT) Given Market Outperform Rating at JMP Securitiesmarketbeat.com - April 18 at 2:21 PMJonestrading Begins Coverage on Rezolute (NASDAQ:RZLT)marketbeat.com - April 18 at 8:35 AMOptimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment Prospectsmarkets.businessinsider.com - April 18 at 5:30 AMCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?investorplace.com - April 15 at 3:43 PMRezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 10 at 4:10 PMRezolute (NASDAQ:RZLT) Earns Buy Rating from Analysts at Maxim Groupmarketbeat.com - April 9 at 8:23 AMInsiders Are Buying These 5 Penny Stocksinsidermonkey.com - April 4 at 8:51 AMRezolute, Inc. (NASDAQ:RZLT) Short Interest Updatemarketbeat.com - March 27 at 9:30 PMRezolute Reaches US$75m Market Cap Benefiting Insider Stock Buyingfinance.yahoo.com - March 27 at 8:51 AM3 Stocks Insiders Are Buying That Analysts Love (RZLT)insidertrades.com - March 26 at 12:55 PMRezolute's chief medical officer buys $18.8k in company stockinvesting.com - March 20 at 5:29 PMDaron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stockinsidertrades.com - March 20 at 7:32 AMBrian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stockinsidertrades.com - March 19 at 5:40 AMInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 36,503 Shares of Stockinsidertrades.com - March 15 at 11:42 AMRezolute, Inc. (NASDAQ:RZLT) CFO Acquires $96,500.00 in Stockinsidertrades.com - March 11 at 7:22 AMRezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)globenewswire.com - March 6 at 7:30 AMRezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning Callsbenzinga.com - February 22 at 12:13 PMRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Updatefinanznachrichten.de - February 16 at 9:03 AMWe're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Ratefinance.yahoo.com - February 15 at 7:59 AMRezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Updatefinance.yahoo.com - February 13 at 7:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Aprea TherapeuticsNASDAQ:APREAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Liminal BioSciencesNASDAQ:LMNLLiminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.RezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.